Episode 28

Viral Hepatitis Data From AASLD 2020 – Rapid Recap

Hear insights from Norah Terrault, MD, MPH, on some of the most important viral hepatitis data reported at the virtual American Association for the Study of Liver Diseases (AASLD) 2020 annual meeting, including new findings on HBV treatment and management, hepatocellular carcinoma risk, and emerging approaches to HCV care in underserved populations.

Decera Clinical Education Infectious Disease Podcast · Norah Terrault MD MPH

November 25, 202050m 14s

Audio is streamed directly from the publisher (afp-928689-injected.calisto.simplecastaudio.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.

Original episode page

Show Notes

In this episode, Dr. Terrault discusses results from key viral hepatitis studies reported at the American Association for the Study of LiverDiseases (AASLD) 2020 annual conference, The Liver Meeting Digital Experience, including new findings on HBV treatment and management, hepatocellular carcinoma risk, and emerging approaches to HCV care in underserved populations.

Presenter:

Norah Terrault, MD, MPH
Professor of Medicine
Chief of Gastrointestinal and Liver Diseases
University of Southern California
Los Angeles, California

Content based on a CME program supported by an independent educational grant from Gilead Sciences, Inc.

Link to full program:
https://bit.ly/37bBrce

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Topics

embedded navigation hcv pwidhcc risk hcvhepatitis c virushepatitis b surface antigen loss na withdrawalhepatocellular carcinoma riskhbsag lossreal-c hcvhbv nucleos(t)ide analogue discontinuationhbv na treatment discontinuationhcv herohcv hero studyhepatitis b surface antigen lossembedded treatment hcv pwudhbv tenofovir df withdrawaltenofovir alafenamide hbv perinatal transmissionafp hcc risk hcvhbv hbsag lossembedded navigation hcv pwudhcc risk hcv svrrg6346hepatocellular carcinomaselgantolimodamap hcc risk scorechronic hepatitis bembedded treatment hcv pwidhbv tdf withdrawaltenofovir alafenamide hbv vertical transmissionledipasvir/sofosbuvirtenofovir df and peginterferon hbvamap hepatocellular carcinoma risktenofovir alafenamide hbv pregnancyhbv peginterferonjnj-6379hcv people who inject drugshcc risk hcv svr daashcv treatment adherence pwidchbhbvhcvhcchcv stage 3 cirrhosis hcc risknasvacabi-h073hepatitis b virusgsk3228836

← All episodes of Decera Clinical Education Infectious Disease Podcast